SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company.

SuperGen has plenty of cash from Dacogen decitabine royalties and needs a cancer pipeline to fill the gap if Dacogen cannot add new indications that will extend its Orphan exclusivity.